Clarke, Noel W.

Abiraterone for prostate cancer not previously treated with hormone therapy

James, N. D., de Bono, J. S., Spears, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Ritchie, A. W. S., Amos, C. L., Gilson, C., Jones, R. J., et al. (2017) · New England Journal of Medicine

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 1,801

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Clarke, N. W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N., Loredo, E., Procopio, G., de Menezes, J., Girotto, G., Arslan, C., et al. (2022) · NEJM Evidence

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 426

Resonant Mie Scattering (RMieS) correction of infrared spectra from highly scattering biological samples

Bassan, P., Kohler, A., Martens, H., Lee, J., Byrne, H. J., Dumas, P., Gazi, E., Brown, M., Clarke, N., & Gardner, P. (2010) · The Analyst

Spectroscopy Techniques in Biomedical and Chemical ResearchSpectroscopy and Chemometric Analyses

Cited by 375

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

Saad, F., Clarke, N. W., Oya, M., Shore, N., Procopio, G., Guedes, J. D., Arslan, C., Mehra, N., Parnis, F., Brown, E., et al. (2023) · The Lancet Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 326

Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021

Gillessen, S., Armstrong, A., Attard, G., Beer, T. M., Beltran, H., Bjartell, A., Bossi, A., Briganti, A., Bristow, R. G., Bulbul, M., et al. (2022) · European Urology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 130

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial

James, N. D., Sydes, M. R., Mason, M. D., Clarke, N. W., Anderson, J., Dearnaley, D. P., Dwyer, J., Jovic, G., Ritchie, A. W., Russell, J. M., et al. (2012) · The Lancet Oncology

Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment

Cited by 123

Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer.

CLARKE, N. W., McCLURE, J., & GEORGE, N. J. R. (1992) · British Journal of Urology

Bone health and treatmentsBone Metabolism and Diseases

Cited by 78

Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study

Fizazi, K., Clarke, N. W., De Santis, M., Uemura, H., Fay, A. P., Karadurmus, N., Kwiatkowski, M., Alvarez-Fernandez, C., Jiang, S., Sotelo, M., et al. (2026) · Annals of Oncology

Prostate Cancer Treatment and ResearchPI3K/AKT/mTOR signaling in cancer

Cited by 55